Wealthsource Partners LLC increased its holdings in shares of ResMed Inc. (NYSE:RMD) by 17.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,150 shares of the medical equipment provider’s stock after buying an additional 1,080 shares during the period. Wealthsource Partners LLC’s holdings in ResMed were worth $550,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Sawtooth Solutions LLC increased its stake in ResMed by 1.6% during the 2nd quarter. Sawtooth Solutions LLC now owns 3,167 shares of the medical equipment provider’s stock worth $247,000 after buying an additional 49 shares during the period. YorkBridge Wealth Partners LLC increased its stake in ResMed by 4.9% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 69 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in ResMed by 2.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,489 shares of the medical equipment provider’s stock worth $272,000 after buying an additional 82 shares during the period. Toronto Dominion Bank increased its stake in ResMed by 12.8% during the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after buying an additional 197 shares during the period. Finally, Utah Retirement Systems increased its stake in ResMed by 0.8% during the 2nd quarter. Utah Retirement Systems now owns 25,583 shares of the medical equipment provider’s stock worth $1,992,000 after buying an additional 200 shares during the period. 62.02% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $77.05, for a total value of $96,312.50. Following the completion of the transaction, the chief financial officer now owns 64,691 shares in the company, valued at approximately $4,984,441.55. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider David Pendarvis sold 6,364 shares of the company’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $76.94, for a total transaction of $489,646.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 184,693 shares of company stock valued at $15,149,955. Company insiders own 1.77% of the company’s stock.

Shares of ResMed Inc. (NYSE RMD) traded down $0.83 during trading hours on Thursday, hitting $85.01. 656,600 shares of the company’s stock were exchanged, compared to its average volume of 846,192. ResMed Inc. has a 52 week low of $60.13 and a 52 week high of $87.81. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.86 and a current ratio of 4.72. The stock has a market cap of $12,010.00, a P/E ratio of 29.91, a PEG ratio of 1.89 and a beta of 0.78.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company had revenue of $523.66 million for the quarter, compared to the consensus estimate of $506.08 million. During the same period in the prior year, the firm posted $0.62 EPS. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. research analysts expect that ResMed Inc. will post 3.03 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be issued a $0.35 dividend. This represents a $1.40 annualized dividend and a dividend yield of 1.65%. The ex-dividend date of this dividend is Wednesday, November 8th. ResMed’s payout ratio is 56.68%.

A number of equities research analysts have commented on the stock. BMO Capital Markets increased their price objective on shares of ResMed to $82.00 and gave the company a “market perform” rating in a research report on Tuesday. Zacks Investment Research raised shares of ResMed from a “sell” rating to a “hold” rating in a research report on Monday, October 30th. J P Morgan Chase & Co increased their price objective on shares of ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a research report on Monday, October 30th. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a research report on Friday, September 8th. Finally, Barclays increased their price objective on shares of ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. Four research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $68.71.

COPYRIGHT VIOLATION WARNING: “ResMed Inc. (RMD) Stake Boosted by Wealthsource Partners LLC” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/14/resmed-inc-rmd-stake-boosted-by-wealthsource-partners-llc.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.